Literature DB >> 10992000

A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.

S H Chapel1, P Veng-Pedersen, R L Schmidt, J A Widness.   

Abstract

The pharmacodynamics (PD) of the reticulocyte response resulting from phlebotomy-induced erythropoietin (EPO) was investigated in adult sheep. The anemia caused by the controlled phlebotomy (Hb < 4 g/dl, t = 0) resulted in a rapid increase in EPO with peak concentrations from 200 to 1400 mU/ml at 0.5 to 3 days generating a delayed reticulocyte response with peak levels from 9.3 to 14.1% at 2.5 to 5.1 days. The PD EPO-reticulocyte relationship is well described by a simple kinetic model involving 3 relevant physiologic parameters: T(1) = lag-time (0.73 +/- 0.32 days, mean +/- S.D.), T(2) = reticulocyte maturation time (5.61 +/- 1.41 days), and k = EPO efficacy coefficient (0.052 +/- 0.048% g/dl mU/ml/day). Accordingly, 0.52% reticulocytes at 10 g/dl Hb level are generated per day at an EPO concentration of 100 mU/ml. The difference between the T(2) parameter in this study and the maturation time reported for humans may be due to interspecies differences or different technique and experimental conditions. The PD transduction appears largely linear in the observed EPO concentration range, indicating a full utilization of EPO without any significant PD saturation. Also, the EPO concentration versus time profiles resulting from the phlebotomy were similar to exogenous EPO profiles resulting from s.c. therapeutic dosing. This study supports the hypothesis that s.c. EPO dosing is more efficacious than i.v. dosing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992000

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

2.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

3.  A 'bottom-up' approach for endo-PK/PD analysis.

Authors:  S Neelakantan; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2006-10       Impact factor: 1.627

4.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

5.  Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.

Authors:  Balaji Agoram; Anne C Heatherington; Marc R Gastonguay
Journal:  AAPS J       Date:  2006-09-01       Impact factor: 4.009

6.  An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.

Authors:  P Veng-Pedersen; S Chapel; R L Schmidt; N H Al-Huniti; R T Cook; J A Widness
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

7.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

8.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

9.  Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Authors:  Rune V Overgaard; Mats Karlsson; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

10.  Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.